AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

1. (Currently Amended) ~~An~~ pharmaceutical composition comprising an antibacterial aminopyrrolizidine or alkylaminopyrrolizidine compound ~~which is:~~

~~(a) for use in therapy or prophylaxis; and/or~~

~~(b) in a pharmaceutical composition; and/or~~

~~(c) in a unit dosage form; and/or~~

(d) ~~in a form suitable for local or systemic administration~~.

2. (Canceled)

3. (Currently Amended) ~~The compound of claim 1 or claim 2 having~~A pharmaceutical composition according to claim 1 wherein the aminopyrrolizidine or alkylaminopyrrolizidine compound has a saturated or unsaturated (e.g. 6,7-dehydro) aminopyrrolizidine or alkylaminopyrrolizidine nucleus of formula:



4. (Currently Amended) ~~The compound of claim 1 or claim 2 having~~A pharmaceutical composition according to claim 1 wherein the aminopyrrolizidine or alkylaminopyrrolizidine compound has a saturated or unsaturated (e.g. 6,7-dehydro) aminopyrrolizidine or alkylaminopyrrolizidine nucleus of formula:



5. (Currently Amended) ~~The compound of any one of claims 1 to 3 which~~A pharmaceutical composition according to claim 3 wherein the aminopyrrolizidine or alkylaminopyrrolizidine compound is hydroxylated, for example being mono- or dihydroxylated (e.g. at C-2 and/or C-7).

6. (Currently Amended) ~~The compound of any one of claims 1, 2 and 4 which~~A pharmaceutical composition according to claim 4 wherein the aminopyrrolizidine or alkylaminopyrrolizidine compound is hydroxylated, for example being mono- or dihydroxylated (e.g. at C-[[1]]2 and/or C-7).

7. (Currently Amended) A pharmaceutical composition according to claim 1 wherein the aminopyrrolizidine or alkylaminopyrrolizidine compound ~~having~~has the formula:



in which a, b, c, d, e and f indicate the location of optional C=C double bonds, provided, however, that the double bonds are not adjacent and that when one or more double bond(s) are present then the substitution patterns around such bonds do not violate double bond valency, wherein R^1 is amino or alkyl amino, R^2 and R^3 are independently selected from hydrogen, oxo, halo, hydroxy and alkoxy, ~~and wherein the compound is:~~

~~(a) for use in therapy or prophylaxis; and/or~~

~~(b) in isolated or purified form; and/or~~

~~(c) in a pharmaceutical composition; and/or~~

~~(d) in a unit dosage form; and/or~~

~~(e) in a form suitable for local or systemic administration,~~

or a pharmaceutically acceptable salt or derivative thereof.

8. (Currently Amended) ~~The compound of~~A pharmaceutical composition according to claim 7 wherein the alkyl amino is C_1-C_{10} alkyl amino (for example, C_1-C_6 alkyl amino, e.g. C_1-C_4 alkyl amino) and/or the alkoxy is C_1-C_{10} alkoxy (for example, C_1-C_6 alkoxy, e.g. C_1-C_4 alkoxy).

9. (Currently Amended) ~~The compound of~~A pharmaceutical composition according to claim 8 wherein the alkyl amino is a C_1, C_2, C_3, C_4, C_5 or C_6 alkyl amino.

10. (Currently Amended) ~~The compound of any one of claims 7 to 9~~A pharmaceutica composition according to claim 8 wherein the alkoxy is a C_1, C_2, C_3, C_4, C_5 or C_6 alkoxy.

11. (Currently Amended) ~~The compound of any one of claims 7 to 10 wherein the halo is chloro, fluoro, iodo or bromo~~A pharmaceutical composition according to claim 9 wherein the alkoxy is a C_1, C_2, C_3, C_4, C_5 or C_6 alkoxy.

12-17. (Canceled)

18. (Currently Amended) ~~The compound of claim 7~~A pharmaceutical composition according to claim 1, wherein the aminopyrrolizidine or alkylaminopyrrolizidine compound~~which~~ is selected from:

(a) 2,7-dihydroxy-1-methylaminopyrrolizidine:



(b) 2,7-dihydroxy-1-aminopyrrolizidine:



(c) 2-hydroxy-1-aminopyrrolizidine:



(d) 2-hydroxy-1-methylaminopyrrolizidine:



(e) 7-hydroxy-1-aminopyrrolizidine:



(f) 7-hydroxy-1-methylaminopyrrolizidine:



(g) 1α-methylamino-2β-hydroxypyrrolizidine:



(h) 1α-methylamino-7β-hydroxypyrrolizidine:



(i) 1α-amino-2β-hydroxypyrrolizidine;

(j) 1α-amino-7β-hydroxypyrrolizidine;

(k) 1α-amino-2,7β-hydroxypyrrolizidine;

(l) 1α-methylamino-2,7β-hydroxypyrrolizidine;

(m)2-hydroxy-1-amino-6,7-dehydropyrrolizidine.

19. (Currently Amended) ~~The compound of~~A pharmaceutical composition according to claim 7 wherein R^1 is C_1 alkyl amino (methylamino) and R^2 and R^3 are oxo, having the formula:



20. The compound of claim 7 which is saturated and wherein R^1, R^2 and R^3 are as shown below:

R^1	R^2	R^3
Amino	Hydrogen	Hydrogen
Amino	Hydrogen	Oxo
Amino	Hydrogen	Hydroxy
Amino	Hydrogen	Halo
Amino	Hydrogen	Alkoxy
Amino	Oxo	Hydrogen

Amino	Oxo	Oxo
Amino	Oxo	Hydroxy
Amino	Oxo	Halo
Amino	Oxo	Alkoxy
Amino	Hydroxy	Hydrogen
Amino	Hydroxy	Oxo
Amino	Hydroxy	Hydroxy
Amino	Hydroxy	Halo
Amino	Hydroxy	Alkoxy
Amino	Halo	Hydrogen
Amino	Halo	Oxo
Amino	Halo	Hydroxy
Amino	Halo	Halo
Amino	Halo	Alkoxy
Amino	Alkoxy	Hydrogen
Amino	Alkoxy	Oxo
Amino	Alkoxy	Hydroxy
Amino	Alkoxy	Halo
Amino	Alkoxy	Alkoxy
Methylamino	Hydrogen	Hydrogen
Methylamino	Hydrogen	Oxo
Methylamino	Hydrogen	Hydroxy
Methylamino	Hydrogen	Halo
Methylamino	Hydrogen	Alkoxy
Methylamino	Oxo	Hydrogen
Methylamino	Oxo	Oxo
Methylamino	Oxo	Hydroxy
Methylamino	Oxo	Halo
Methylamino	Oxo	Alkoxy
Methylamino	Hydroxy	Hydrogen

Methylamino	Hydroxy	Oxo
Methylamino	Hydroxy	Hydroxy
Methylamino	Hydroxy	Halo
Methylamino	Hydroxy	Alkoxy
Methylamino	Halo	Hydrogen
Methylamino	Halo	Oxo
Methylamino	Halo	Hydroxy
Methylamino	Halo	Halo
Methylamino	Halo	Alkoxy
Methylamino	Alkoxy	Hydrogen
Methylamino	Alkoxy	Oxo
Methylamino	Alkoxy	Hydroxy
Methylamino	Alkoxy	Halo
Methylamino	Alkoxy	Alkoxy
Alkylamino	Hydrogen	Hydrogen
Alkylamino	Hydrogen	Oxo
Alkylamino	Hydrogen	Hydroxy
Alkylamino	Hydrogen	Halo
Alkylamino	Hydrogen	Alkoxy
Alkylamino	Oxo	Hydrogen
Alkylamino	Oxo	Oxo
Alkylamino	Oxo	Hydroxy
Alkylamino	Oxo	Halo
Alkylamino	Oxo	Alkoxy
Alkylamino	Hydroxy	Hydrogen
Alkylamino	Hydroxy	Oxo
Alkylamino	Hydroxy	Hydroxy
Alkylamino	Hydroxy	Halo
Alkylamino	Hydroxy	Alkoxy
Alkylamino	Halo	Hydrogen

Alkylamino	Halo	Oxo
Alkylamino	Halo	Hydroxy
Alkylamino	Halo	Halo
Alkylamino	Halo	Alkoxy
Alkylamino	Alkoxy	Hydrogen
Alkylamino	Alkoxy	Oxo
Alkylamino	Alkoxy	Hydroxy
Alkylamino	Alkoxy	Halo
Alkylamino	Alkoxy	Alkoxy

21. (Canceled)

22. (Currently Amended) ~~The compound of claim 21~~A pharmaceutical composition according to claim 20 wherein the aminopyrrolizidine or alkylaminopyrrolizidine compound~~which~~ is 1,2-dehydro-, 5,6-dehydro-, 6,7-dehydro or 7,8-dehydro.

23-25. (Canceled)

26. (Currently Amended) A method of treating or preventing a bacterial infection comprising administering to a patient in need thereof a therapeutically effective amount of the ~~compound as defined in any one of the preceding claims~~the pharmaceutical composition according to claim 1.

27. (Original) The method of claim 26 wherein the bacterial infection comprises infection with a Gram-positive bacterium.

28. (Original) The method of claim 27 wherein the Gram-positive bacterium is a low G+C Gram-positive bacterium.

29. (Original) The method of claim 28 wherein the low G+C Gram-positive bacterium is a Staphylococcus spp. or a *Bacillus* spp..

30. (Original) The method of claim 29 wherein the *Staphylococcus* spp. is *S. aureus* or *S. epidermidis*).

31. (Currently Amended) The method of claim [[29]]30 wherein the *Staphylococcus* spp. is MRSA, for example selected from any of C-MSRA1, C-MRSA2, C-MRSA3, C-MSRA4, Belgian MRSA, Swiss MRSA and any of the EMRSA strains.

32. (Original) The method of claim 29 wherein the *Bacillus* spp. is *Bacillus anthracis*.

33-41. (Canceled)